Oseni Approval History
FDA Approved: Yes (First approved January 25, 2013)
Brand name: Oseni
Generic name: alogliptin and pioglitazone
Dosage form: Tablets
Previous Name: SYR-322/Actos
Company: Takeda Pharmaceutical Company Limited
Treatment for: Diabetes, Type 2
Oseni (alogliptin and pioglitazone) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and thiazolidinedione fixed-dose combination for the treatment of type 2 diabetes.
Development History and FDA Approval Process for Oseni
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.